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Following publication of the original article \[[@CR1]\], the authors submitted a corrected version of Table [4](#Tab1){ref-type="table"} (see below), as the original version contained a mistake.Table 4Comparison of outcome results from terminated CVOTs in comparison to placeboSAVOR-TIMI53 \[1, 2\]EXAMINE \[3, 4\]TECOS \[5\]ELIXA \[6\]EMPA-REG OUTCOME \[7\]LEADER \[8\]ClassHR (95% CI)ClassHR (95% CI)ClassHR (95% CI)ClassHR (95% CI)ClassHR (95% CI)ClassHR (95% CI)p valuep valuep valuep valuep valuep valueCardiovascular endpoints Primary composite MACECV death, MI, or stroke1.00 (0.89--1.12)\
0.99CV death, MI, or stroke0.96 (≤ 1.16)\
0.32CV death, MI, UA, or stroke0.98 (0.89--1.08)\
0.65CV death, MI, UA, or stroke1.02 (0.89--1.17)\
0.81CV death, MI, or stroke0.86 (0.74--0.99)\
0.04^a^CV death, MI, or stroke0.87 (0.78--0.97)\
0.01 Cardiovascular deathPrimary endpoint1.03 (0.87--1.22)\
0.72Primary endpoint0.79 (0.60--1.04)\
0.10Secondary endpoint1.03 (0.89--1.19)\
0.71Primary endpoint0.98 (0.78--1.22)\
0.85Primary endpoint0.62 (0.49--0.77)\
\< 0.001Primary endpoint0.78 (0.66--0.93)\
0.007 Myocardial infarctionPrimary endpoint0.95 (0.80--1.12)\
0.52Primary endpoint1.08 (0.88--1.33)\
0.47Secondary endpoint0.95 (0.81--1.11)\
0.49Primary endpoint1.03 (0.87--1.22)\
0.71Primary endpoint0.87 (0.70--1.09)\
0.23Primary endpoint0.86 (0.73--1.00)\
0.046 StrokePrimary endpoint1.11 (0.88--1.39)\
0.38Primary endpoint0.91 (0.55--1.50)\
0.71Secondary endpoint0.97 (0.79--1.19)\
0.76Primary endpoint1.12 (0.79--1.58)\
0.54Primary endpoint1.18 (0.89--1.56)\
0.26Primary endpoint0.86 (0.71--1.06)\
0.16 Hospitalization for unstable anginaSecondary endpoint1.19 (0.89--1.60)\
0.24Secondary endpoint0.90 (0.60--1.37)\
0.632Secondary endpoint0.90 (0.70--1.16)\
0.42Primary endpoint1.11 (0.47--2.62)\
0.81Secondary endpoint0.99 (0.74--1.34)\
0.97Extended\
primary endpoint0.98 (0.76--1.26)\
0.87 Hospitalization for heart failureSecondary endpoint1.27 (1.07--1.51)\
0.007Extended primary endpoint1.19 (0.90--1.58)\
0.220Secondary endpoint1.00 (0.83--1.20)\
0.98Secondary endpoint0.96 (0.75--1.23)\
0.75Secondary endpoint0.65 (0.50--0.85)\
0.002Extended\
primary endpoint0.87 (0.73--1.05)\
0.14Event rate (%) active groupEvent rate (%) active groupEvent rate (%) active groupEvent rate (%) active groupEvent rate (%) active groupEvent rate (%) active group Primary composite MACE7.311.39.613.410.513.0No. (%)\
p valueNo. (%)\
p valueNo. (%)\
p valueNo. (%)\
p valueNo. (%)\
p valueNo. (%)\
p valueNon-cardiovascular endpoints Renal event5.8\
0.040.9\
0.881.4\
--1.6\
--5.2\
--5.7\
0.003 Acute pancreatitis0.3\
0.770.4\
0.50.3\
0.070.2\
--0.3^b^\
--0.4\
0.44 Hypoglycemia events15.3\
\< 0.0016.7\
0.742.2\
0.3316.6\
0.142.82.4\
0.02SUSTAIN 6 \[9\]EXSCEL \[10\]DEVOTE \[11\]CANVAS program \[12\]ACE \[13\]ClassHR (95% CI)\
p valueClassHR (95% CI)\
p valueClassHR (95% CI)\
p valueClassHR (95% CI)\
p valueClassHR (95% CI)\
p valueCardiovascular endpoints Primary composite MACECV death, MI, or stroke0.74 (0.58--0.95)\
0.02^a^CV death, MI or stroke0.91 (0.83--1.00)\
0.06^a^CV death, MI or stroke0.91 (0.78--1.06)\
\< 0.001CV death, MI or stroke0.86 (0.75--0.97)\
0.02^a^CV death, MI, stroke, UA and HF0.98 (0.86--1.11)\
0.73 Cardiovascular deathPrimary endpoint0.98 (0.65--1.48)\
0.92Secondary endpoint0.88 (0.76--1.02)Primary endpoint0.96 (0.76--1.21)\
0.71Primary endpoint0.87 (0.72--1.06)Secondary endpoint0.89 (0.71--1.11)\
0.29 Myocardial infarctionPrimary endpoint0.74 (0.51--1.08)\
0.12Secondary endpoint0.97 (0.85--1.10)Primary endpoint0.85 (0.68--1.06)\
0.15Primary endpoint0.89 (0.73--1.09)Secondary endpoint1.12 (0.87--1.46)\
0.38 StrokePrimary endpoint0.61 (0.38--0.99)\
0.04Secondary endpoint0.85 (0.70--1.03)Primary endpoint0.90 (0.65--1.23)\
0.50Primary endpoint0.87 (0.69--1.09)Secondary endpoint0.97 (0.70--1.33)\
0.83 Hospitalization for unstable anginaExtended primary endpoint0.82 (0.47--1.44)\
0.49----Primary endpoint0.95 (0.68--1.31)\
0.74----Secondary endpoint1.02 (0.82--1.26)\
0.87 Hospitalization for heart failureExtended primary endpoint1.11 (0.77--1.61)\
0.57Secondary endpoint0.94 (0.78--1.13)----Secondary endpoint0.67 (0.52--0.87)Secondary endpoint0.89 (0.63--1.24)\
0.48Event rate (%) active groupEvent rate (%) active groupEvent rate (%) active groupEvent rate (%) active groupEvent rate (%) active group Primary composite MACE6.611.48.526.9^d^14.4No. (%)\
p valueNo. (%)\
p valueNo. (%)\
p valueNo. (%)\
p valueNo. (%)\
p valueNon-cardiovascular endpoints Renal event3.9\
--55 (0.7)3.8\
--19.7^d^\
0.32-- Acute pancreatitis0.55\
--26 (0.4)--\
--0.5^d^\
0.63-- Hypoglycemia events22.4^c^\
--247 (3.4)4.9\
\< 0.001^a^56.0^d^\
0.2054 (2)\
0.95^a^Superiority test^b^Average across all age ranges^c^Severe hypoglycaemia as defined by ADA^d^Number of participants per 1000 patient-years

The original article has been corrected.
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